Cancer of the Colon
8
1
1
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.5%
1 terminated out of 8 trials
85.7%
-0.8% vs benchmark
0%
0 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (8)
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
Endoscopic Optical Coherence Tomography for Screening and Diagnosis of Colorectal Precancerous and Malignant Polyps
Test of CD47-SIRPα Inhibitors on the Immune Microenvironment Colon Cancer
Opt-In Versus Opt-Out for Colorectal Cancer Screening Outreach
AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer
Colorectal Cancer Screening in a Community Health Setting
Behavioral Economic Incentives and Cancer Health Risk Assessment
Behavioral Economic Approaches to Increase Colorectal Cancer Screening